Glioblastoma Multiforme Market Growth, Trends, and Forecast 2025 | Top key players - Pfizer, Genentech, Amgen.

The Global Glioblastoma Multiforme Market reached USD 2.4 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 4.5 billion by 2031. The global glioblastoma multiforme market is expected to exhibit a CAGR of 8.6% during the forecast period 2024-2031.

Glioblastoma Multiforme Market report, published by DataM Intelligence, delivers detailed insights and analysis on major market trends, growth prospects, and emerging challenges. With a strong focus on providing actionable intelligence, DataM Intelligence enables businesses to make well-informed decisions and maintain a competitive edge. By blending both qualitative and quantitative research approaches, the company offers thorough reports that support clients in navigating complex market environments, driving strategic expansion, and capitalizing on new opportunities in today's rapidly evolving global landscape.

The Glioblastoma Multiforme (GBM) Market refers to the industry surrounding the diagnosis, treatment, and management of this aggressive brain tumor. GBM is known for its rapid growth and resistance to treatment, leading to high demand for innovative therapies. The market includes surgical, radiation, and emerging drug treatments, as well as diagnostic tools, with ongoing research driving advancements in care options.

Request a Free Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://datamintelligence.com/download-sample/glioblastoma-multiforme-market?sz

Market opportunities and Growth Drivers:

Rising Incidence of Glioblastoma to Drive the Growth of the Glioblastoma Multiforme Market

The increasing number of glioblastoma multiforme (GBM) cases worldwide is a growing concern, driven by factors like exposure to ionizing radiation, genetic predispositions, and environmental influences. As a result, there is a heightened demand for effective treatment options, which is expected to significantly drive the expansion of the global GBM treatment market in the coming years.

For example, the National Brain Tumor Society's 2022 report highlights just how challenging glioblastoma (GBM) is to treat. It's one of the deadliest and most resistant types of cancer, making up nearly half of all primary malignant brain tumors. In the U.S., more than 10,000 people are expected to lose their lives to GBM each year. Unfortunately, the five-year survival rate for those diagnosed with this condition is a mere 6.8%, and the average survival time is only around 8 months. As the prevalence of GBM continues to rise and more lives are lost, the market for GBM treatments is poised for substantial growth in the years ahead.

Glioblastoma Multiforme Market Recent Development:

In June 3, 2023, Chimeric Therapeutics announced the initiation of a Phase IB clinical trial for CHM 1101 (CLXT CAR T) cell therapy. This trial is designed to evaluate the safety and efficacy of CHM 1101 in patients with recurrent or progressive glioblastoma multiforme (GBM), a highly aggressive and often fatal form of primary brain cancer. The clinical trial marks a significant step in exploring immunotherapy options for treating this difficult-to-treat cancer.

In March 8, 2023, Genenta Science received orphan drug status from the FDA for its Temferon cell therapy. This designation is aimed at treating glioblastoma multiforme (GBM) patients, further highlighting the growing interest in developing gene therapies and cell-based treatments for this challenging cancer. Orphan drug status grants benefits such as market exclusivity and tax incentives, which will help facilitate the continued development of Temferon.

List of the Key Players in the Glioblastoma Multiforme Market:

Pfizer, Genentech, Amgen, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC., Sun Pharmaceutical Industries, Ltd., F. Hoffmann-Le Roche AG, Amneal Pharmaceuticals and Karyopharm Therapeutics, Inc., among others.

Research Process:

Both primary and secondary data sources have been used in the global Glioblastoma Multiforme Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/glioblastoma-multiforme-market

Segment Covered in the Glioblastoma Multiforme Market:

By Treatment type (Drugs (Temozolomide, Bevacizumab, Carmustine, Others), Immunotherapy, Electric field therapy, Others), By Type of molecule (Small molecules, Biologics), By Route of administration (Oral, Parenteral), By End-user (Hospitals, Clinics, Others)

Regional Analysis for Glioblastoma Multiforme Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

People Also Ask:

Most Frequently Asked Questions in the Glioblastoma Multiforme Market Research Industry:

➠ What are the global figures for sales, production, consumption, imports, and exports in the Glioblastoma Multiforme market?

➠ Who are the top manufacturers in the global Glioblastoma Multiforme industry, and what is their current status in terms of production capacity, output, sales performance, pricing structure, cost analysis, profit margins, and overall revenue?

➠ What key opportunities are available for vendors in the Glioblastoma Multiforme market, and what challenges are they likely to encounter?

➠ Which application areas, end-user segments, or product types are projected to experience significant growth, and how is the market share distributed among them?

➠ What are the major drivers and barriers influencing the growth trajectory of the Glioblastoma Multiforme market?

➠ What are the primary sales, marketing, and distribution strategies used across the global Glioblastoma Multiforme industry landscape?

Browse More Reports: https://www.datamintelligence.com/research-report/glioblastoma-multiforme-market

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.